| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President | CFO and Head of Strategy
2 companies
Sridhar Kosaraju is President at PEN, with reported holdings spanning 2 companies. Sridhar Kosaraju's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $54.5M at current prices.
Our model assigns Sridhar Kosaraju a strong insider score of 90/100, based on 10 past trades. Over a 12-month horizon, all 10 of those trades were profitable, with an average 12-month return of +76.0%.
Sridhar Kosaraju's largest disclosed position is in PEN as President, worth about $50.1M. The PEN filings lean toward selling, a net 140,000 shares.
Sridhar Kosaraju has 44 Form 4 filings on record from November 2016 to June 2026, across 2 companies: Director at 10x Genomics (TXG), 2019–2026; President at Penumbra (PEN), 2016–2020.
The 151 reported transactions were 128 open-market sales, 6 stock awards, 4 option or other derivative awards and 4 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 30 sales worth about $17.4M.
The largest open-market sale was 21,956 shares of PEN at an average $105.27 on November 20, 2017, about $2.3M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $150.38 | $225,568.95 | -33.3% | -50.5% | -75.8% | |
| Nov 24, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $150.06 | $225,084.45 | -25.0% | -47.9% | -76.3% | |
| Oct 25, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $166.32 | $249,477.74 | -20.0% | -43.9% | -84.3% | |
| Sep 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $159.04 | $238,561.99 | -16.7% | -7.7% | -81.8% | |
| Aug 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $162.06 | $243,087.50 | -14.3% | -9.7% | -78.4% | |
| Jul 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $183.67 | $275,500.35 | -12.5% | -10.7% | -80.9% | |
| Jun 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $199.95 | $299,923.18 | -11.1% | -20.1% | -76.9% | |
| May 24, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $161.16 | $241,746.00 | -10.0% | -1.5% | -72.5% | |
| Apr 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $193.08 | $289,623.12 | -9.1% | -4.2% | -72.2% | |
| Mar 23, 2021 | TXG 10x Genomics, Inc. | Director | Sell | 1,500 | $174.63 | $261,939.00 | -8.3% | +13.6% | -60.8% |